Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)
Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)
Status: Enrolling
Updated:  12/31/1969
Univ of Massachusetts Med School
mi
from
Worcester, MA
Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)
Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)
Status: Enrolling
Updated: 12/31/1969
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
Imaging Biomarkers in ALS
A Longitudinal Study of Imaging Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Imaging Biomarkers in ALS
A Longitudinal Study of Imaging Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status: Enrolling
Updated:  12/31/1969
Tampa General Hospital
mi
from
Tampa, FL
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status: Enrolling
Updated: 12/31/1969
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status: Enrolling
Updated:  12/31/1969
University of South Florida
mi
from
Tampa, FL
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status: Enrolling
Updated: 12/31/1969
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status: Enrolling
Updated:  12/31/1969
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
mi
from
Torrance, CA
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status: Enrolling
Updated: 12/31/1969
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status: Enrolling
Updated:  12/31/1969
University of Louisville
mi
from
Louisville, KY
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status: Enrolling
Updated: 12/31/1969
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status: Enrolling
Updated:  12/31/1969
Bayfront Health St. Petersburg
mi
from
Saint Petersburg, FL
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Status: Enrolling
Updated: 12/31/1969
Bayfront Health St. Petersburg
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy
Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy
Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated:  12/31/1969
Texas Neurology, PA
mi
from
Dallas, TX
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated: 12/31/1969
Texas Neurology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Answer ALS: Individualized Initiative for ALS Discovery
Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of a Tele-Rehabilitation Service Program
Joint Gertner ReAbility Online and Mayo Clinic Feasibility Study: Evaluation of a Tele-Rehabilitation Service Program
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Evaluation of a Tele-Rehabilitation Service Program
Joint Gertner ReAbility Online and Mayo Clinic Feasibility Study: Evaluation of a Tele-Rehabilitation Service Program
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
Miami Children's Hospital
mi
from
Miami, FL
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
Miami Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
Child Neurology Center - NW F
mi
from
Pensacola, FL
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
Child Neurology Center - NW F
mi
from
Pensacola, FL
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
Oregon Health Services University
mi
from
Portland, OR
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
Oregon Health Services University
mi
from
Portland, OR
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
Le Bonheur Children's Hospital
mi
from
Memphis, TN
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
Le Bonheur Children's Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
Texas Scottish Rite Hospital for Children
mi
from
Dallas, TX
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
Texas Scottish Rite Hospital for Children
mi
from
Dallas, TX
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
Granger Medical Clinic
mi
from
Riverton, UT
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
Granger Medical Clinic
mi
from
Riverton, UT
Click here to add this to my saved trials
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated:  12/31/1969
Mary Bridge Children's Hospital
mi
from
Tacoma, WA
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status: Enrolling
Updated: 12/31/1969
Mary Bridge Children's Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
Department of Neurology, Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
Department of Neurology, Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
Hospital for special care, New Britain
mi
from
New Britain, CT
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
Hospital for special care, New Britain
mi
from
New Britain, CT
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
Department of Neurology,University of Minnesota
mi
from
Minneapolis, MN
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
Department of Neurology,University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Rehabilitation Institute
mi
from
Spokane, WA
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Rehabilitation Institute
mi
from
Spokane, WA
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
Departement of Neurology, UZ Leuven
mi
from
Leuven,
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
Departement of Neurology, UZ Leuven
mi
from
Leuven,
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
Department of Neurology, McKnight Brain Institute
mi
from
Gainesville, FL
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
Department of Neurology, McKnight Brain Institute
mi
from
Gainesville, FL
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
Department of Neurology and Psichiatry, Saint Louis University
mi
from
Saint Louis, MO
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
Department of Neurology and Psichiatry, Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated:  12/31/1969
Peripheral Neuropathy Center, Neurological Institue Building, Columbia University Medical Center
mi
from
New York, NY
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months
Status: Enrolling
Updated: 12/31/1969
Peripheral Neuropathy Center, Neurological Institue Building, Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Long-Working Distance OCT for Children
Long-Working Distance OCT System With Fixation Alignment for Pediatric Imaging
Status: Enrolling
Updated:  12/31/1969
Duke Eye Center, Duke University Health System
mi
from
Durham, NC
Long-Working Distance OCT for Children
Long-Working Distance OCT System With Fixation Alignment for Pediatric Imaging
Status: Enrolling
Updated: 12/31/1969
Duke Eye Center, Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Trials, Inc.
mi
from
Little Rock, AR
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Trials, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Austin Epilepsy Care Center
mi
from
Austin, TX
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Austin Epilepsy Care Center
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Xenosciences Inc
mi
from
Phoenix, AZ
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Xenosciences Inc
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Banner - University Medical Center Phoenix
mi
from
Phoenix, AZ
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Banner - University Medical Center Phoenix
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Neuro-Pain Medical Center
mi
from
Fresno, CA
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Neuro-Pain Medical Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Bradenton Research Center
mi
from
Bradenton, FL
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Bradenton Research Center
mi
from
Bradenton, FL
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
NW FL Clinical Research Group, LLC
mi
from
Gulf Breeze, FL
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
NW FL Clinical Research Group, LLC
mi
from
Gulf Breeze, FL
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Georgia Neurology and Sleep Medicine Associates
mi
from
Suwanee, GA
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Georgia Neurology and Sleep Medicine Associates
mi
from
Suwanee, GA
Click here to add this to my saved trials